These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15644478)

  • 21. Reducing patient drug acquisition costs can lower diabetes health claims.
    Mahoney JJ
    Am J Manag Care; 2005 Aug; 11(5 Suppl):S170-6. PubMed ID: 16111439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlling prescription drug expenditures: a report of success.
    Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
    Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of a pharmacy benefit to a managed Medicaid population.
    Smith WW; Perry SC
    Med Interface; 1995 Dec; 8(12):84-7, 97. PubMed ID: 10153524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease.
    Nair KV; Wolfe P; Valuck RJ; McCollum MM; Ganther JM; Lewis SJ
    J Manag Care Pharm; 2003; 9(2):123-33. PubMed ID: 14613341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of managed care on pharmacy practice.
    Schafermeyer KW
    Pharm Pract Manag Q; 2000 Jan; 19(4):99-116. PubMed ID: 10787569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between quality and utilization in managed care.
    Scholle SH; Mardon R; Shih SC; Pawlson LG
    Am J Manag Care; 2005 Aug; 11(8):521-7. PubMed ID: 16095438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization.
    Sun SX; Lee KY; Bertram CT; Goldstein JL
    Curr Med Res Opin; 2007 Aug; 23(8):1859-66. PubMed ID: 17605893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting.
    Zarowitz BJ; Stebelsky LA; Muma BK; Romain TM; Peterson EL
    Pharmacotherapy; 2005 Nov; 25(11):1636-45. PubMed ID: 16232025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of formularies on clinical innovation.
    Goodwin FK
    J Clin Psychiatry; 2003; 64 Suppl 17():11-4. PubMed ID: 14680421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact on drug costs and utilization of a clinical pharmacist in a multisite primary care medical group.
    Walker S; Willey CW
    J Manag Care Pharm; 2004; 10(4):345-54. PubMed ID: 15298532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.
    Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD
    Med Care; 2017 Feb; 55(2):191-198. PubMed ID: 27579915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new method for determining patient payments for outpatient drugs.
    Goldman DP; Lakdawalla D
    Am J Manag Care; 2002 Feb; 8(2):125, 128, 130. PubMed ID: 11853200
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmaceutical step-therapy interventions: a critical review of the literature.
    Motheral BR
    J Manag Care Pharm; 2011 Mar; 17(2):143-55. PubMed ID: 21348547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of incentive-based formularies on drug utilization and spending.
    Sandy LG; Heady T
    N Engl J Med; 2004 Mar; 350(10):1057. PubMed ID: 15002122
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of three-tier formulary adoption on medication continuation and spending among elderly retirees.
    Huskamp HA; Deverka PA; Landrum MB; Epstein RS; McGuigan KA
    Health Serv Res; 2007 Oct; 42(5):1926-42. PubMed ID: 17850526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consumer understanding and satisfaction associated with a 3-tier prescription drug benefit.
    Olson BM; Malone DC; Zachary WM; Coons SJ
    J Manag Care Pharm; 2005; 11(6):480-92. PubMed ID: 15998165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Data-based pharmacy utilization review identifies those at-risk, improves care, cuts utilization.
    Data Strateg Benchmarks; 1998 May; 2(5):74-6. PubMed ID: 10345375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Simple method to detect factors influencing drug expenditures].
    Lustig A
    Harefuah; 2004 Jan; 143(1):28-32, 85. PubMed ID: 14748285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.